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Background: Bhutan has been engaged in good-quality cytology-based cervical screening since 2000 and has
vaccinated >90% girls against human papillomavirus (HPV) since 2010. We explored the characteristics associated
with lack of previous screening and screening coverage in women age ≥25 years.
Methods: Women were invited at home or during their attendance at 2 outpatient clinics, in the capital, Thimphu,
and nearby Lungthenphu. Age-adjusted odds ratios for lack of previous screening by selected characteristics were
computed among 1,620 participating women. In Thimphu an invitation registry allowed to estimate screening
history not only among participating women but also among additional 500 women who did not accept to join
our study.
Results: Among women who had a Pap smear, lack of previous screening was associated with age <35 or ≥45 years.
It was also associated with some occupations; being single, or widowed/separated; and presence of HPV infection.
Multiparity and use of contraceptive methods were associated with having been screened. In women invited at home
in Thimphu screening history substantially differed by participation. Past screening attendance was 59% among
women recruited in the 2 clinics, 53% in women who were invited from home and accepted the invitation, but only
25% in those who refused it. Based on all women recruited from home the estimate of population-based coverage in
Thimphu is 34% (95% CI: 31-37).
Conclusions: Transition from an opportunistic screening to an all-reaching population-based screening is yet to be
achieved in Bhutan, even in the capital. Better ways to target never-screened women are needed.
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Cervical cancer represents the most common cancer
among women in Bhutan, with a world age-standardized
incidence rate of 13 cases per 100,000 person years [1].
Cervical cancer incidence is likely to be underestimated
on account of the incomplete establishment of the na-
tional cancer registry. The age-standardized prevalence
of human papillomavirus (HPV) infection in the general
female population in Bhutan is 26%, ranging from 33%
below age 25 years and 19% at age 45 and above [2]. It is
one of the most elevated HPV prevalence among Asian* Correspondence: franceschi@iarc.fr
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unless otherwise stated.countries [3-9]. It is therefore very appropriate that the
country (634,982 inhabitants) has seriously engaged in
cervical cancer prevention [10]. Bhutan was the first
low/middle-income country to start in 2010 a nation-
wide school-based program of vaccination against HPV
and has achieved vaccination-coverage of 92% among 12
to 18 year old girls [11].
Bhutan has also been on the front line in the second-
ary prevention of cervical cancer: a national cytology-
based screening program, including quality control of
Pap smear findings, and systematic recall of screening-
positive women for colposcopy and, if necessary, biop-
sies and treatment, was launched in 2000 [10]. No active
call/recall system is in place but a Pap smear is recom-
mended every three years to women aged 20-60 yearsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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assistants, nurses, and medical doctors in national refer-
ral hospitals and district hospitals through maternal and
child health clinics. Although Pap smear campaigns are
occasionally conducted in rural and high-altitude areas,
the majority of screening activity is concentrated in the
district of the capital, Thimphu, which hosts approxi-
mately one sixth of the Bhutanese population. The only
information on the performance of cervical cancer
screening in Bhutan is a recent publication that shows
poor knowledge of and low participation in cervical can-
cer screening among female university graduates, mainly
below age 25 years [10].
The aims of the present study were to provide an esti-
mate of screening coverage in Thimphu and explore the
characteristics associated with lack of previous screening
among women age 25 or older. The evaluation of screening
was part of a large HPV survey carried out by the Jigme
Dorji Wangchuck National Referral Hospital (JDWNRH),
Thimphu, in collaboration with the Ministry of Health of
Bhutan, and the International Agency for Research on
Cancer (IARC) to monitor future impact of HPV vaccin-
ation and the transition from cytology to HPV testing in
cervical cancer screening program.
Methods
Between December 2011 and October 2012, 2,505 sexu-
ally active women age 18-69 years underwent conven-
tional cytology and HPV testing in JDWNRH, Thimphu,
and in the Hospital of Lungthenphu, a satellite town in
the district of Thimphu, to provide baseline HPV preva-
lence prior to HPV vaccination. Study procedures have
been described elsewhere [2]. In brief, women in both
study areas were recruited in two ways (Figure 1). Resi-
dents of pre-defined areas surrounding the two hospitals
were visited at home by social workers and invited to
join the study (participation: 31% in Thimphu and 45%
in Lungthenphu). Women consulting outpatient clinics
in the two hospitals for cervical screening (mainly ante-
natal care or family planning clinics) were invited to join
the study (participation ~ 100%). Following signature of
an informed consent form, a structured questionnaire
including information on screening history and other
socio-demographic and lifestyle characteristics was admin-
istered to study participants. Testing for 44 HPV types
was made using a general primer GP5+/6+ -mediated
PCR and reverse-line blot hybridization [12].
To investigate screening participation in recom-
mended age groups [13], the present report focused on
1,620 women aged 25 years or above (median age = 33,
inter-quartile range: 28-43) [2]. Among them, 1,003 were
seen at the JDWNRH and 617 at the Lungthenphu Hos-
pital. In Thimphu only, an invitation registry including
age, marital status, and screening history was kept andallowed the additional evaluation of all 500 women
25 years or above who had been invited at home in
Thimphu but did not eventually participate in the study
(Figure 1).
Odds ratios (OR) for lack of previous screening and
corresponding 95% confidence intervals (CI) were com-
puted by unconditional logistic regression adjusted for
5-year age groups. Additional adjustment for type of re-
cruitment did not materially modify any findings. χ2 test
for trend were computed by considering categories as
continuous variables. Effect modification was tested
using the log-likelihood ratio test.
The present study had the approval of both the
Bhutan Research Ethics Board of Health and the IARC
Ethics Committee.
Results
Overall, 661 (40.8%) women who took part in our study
had never been screened before. Table 1 shows the rela-
tionship between screening history and selected women’s
characteristics among study participants. No significant
difference was found between the two study areas. The
lowest fraction of never-screened women was found in
the age group 35-44 years (28.0%). Lack of previous
screening was more frequent in women below age
35 years and those age 45 or above (OR versus age 35-
44 = 2.3; 95% CI:1.8-3.0; and 1.7; 95% CI: 1.2-2.3, re-
spectively). Compared to housewives, the fraction of
never-screened women was larger in shopkeepers/sales-
women (OR = 1.6; 95% CI: 1.1-2.3) and manual workers/
farmers (OR = 1.7; 95% CI: 1.2-2.4). Among ethnic groups,
a relative lack of previous screening was found in Lhot-
sampa (OR vs. Scharchop = 1.6; 95% CI: 1.2-2.1). ORs for
lack of previous screening in single and widowed/sepa-
rated women vs. married women were 4.9 (95% CI: 1.3 -
17.9), and 1.8 (95% CI: 1.2 - 2.6), respectively.
The fraction of never-screened women decreased with
number of pregnancies (χ2 for trend among women who
had been pregnant = 9.8, p = 0.002) and it was largest
among nulligravidae (OR for 0 vs.1 child = 1.9; 95% CI:
1.2-3.2). Fewer never-screened women were found
among current users of any contraceptive method (OR
in users of hormonal contraceptives and other methods
vs. non users = 0.5, 95% CI: 0.3-0.6; and 0.4; 95% CI: 0.3-
0.5, respectively). Finally, lifetime sexual partners (OR
for ≥2 vs 1 = 1.4; 95% CI: 1.0-1.9) and presence of HPV
infection (OR = 1.5; 95% CI: 1.2-1.9) were associated
with lack of previous screening (Table 1).
Education level was positively and significantly associ-
ated with previous screening attendance among women
age 45 or above (χ2 for trend = 5.3 p = 0.02) but not in
younger age groups (p-value for heterogeneity = 0.06)
(Figure 2a). Among 959 previously screened women,
over 70% in every age group reported a Pap smear
Figure 1 Diagram of Bhutan screening survey. 1Tshomo et al, 2014.
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of six years or more (Figure 2b).
Table 2 shows screening history among 1,503 women
from Thimphu according to the place in which they
were contacted and whether they accepted the invita-
tion. Among women invited from home, the invitation
compliance was 31%. It was 28%, 36%, and 31% in
women <35; 35-44, and ≥45, respectively (data not
shown). The largest fraction of lack of screening (75%)
was found among women who were contacted at home
but did not participate in our study (OR for lack of
screening vs women who were contacted at the clinic = 4.3;
95% CI: 3.4-5.6). We notice that only 105 (21.9%) of 479
never-screened women who were invited from home
could eventually be screened for the first time in the
framework of our study. Past screening attendance in
all women contacted at home was 33.9% (95% CI: 30.5-
37.3) and we considered it a proxy of population-based
coverage (Table 2).
Figure 3 shows that the gap in coverage by place in
which women were invited and according to study partici-
pation increased with age. Among women age 45 years or
older screening coverage among all women who were con-
tacted at home was 23.9% (95% CI: 16.9-32.0).
Discussion
Our study showed for the first time that the cervical can-
cer screening program in Thimphu reaches approximatelyone third of women age 25 or older and lack of previous
screening was especially frequent among women who re-
fused the invitation to join our study. They, therefore,
missed the opportunity to be screened for the first time in
the framework of our study.
Among women who took part in our study, previous
screening attendance was relatively high (59%) and better
than in the majority of the 16 low/middle-income popula-
tions who were formerly studied in methodologically
consistent IARC HPV Surveys, i.e., similar recruitment
protocol, age distribution, participation level, and location
in places in which at least minimum cervical screening ex-
pertise and infrastructure were already present [2-9,14-20]
(Figure 4). Much lower levels of screening attendance
were found in Nepal, China, Pakistan, and Vietnam. Only
in Tehran, Iran; Argentina, Concordia; and Lampang,
Thailand was the proportion of previously screened
women larger than in Bhutan. We notice that the propor-
tions of ever-screened women in previous IARC HPV
Surveys were probably affected by a similar participation
bias as in the figure from Bhutan.
Among study participants in Thimphu and Lungthen-
phu, screening history was also significantly affected by
several factors. Past screening attendance was more fre-
quently reported by women 35 to 45 years old than by
younger or older women. Being married, having had
children, and using any type of contraceptive method
were also significantly and positively associated with past
Table 1 Odds ratio and 95% confidence interval for lack of prior cervical cancer screening by selected women’s
characteristics, 1,620 women, Thimphu and Lungthenphu, Bhutan
Variable Total N. (%) of women never screened Odds ratioa 95% confidence interval
All women 1620 661 (40.8) – –
Recruitment area
Thimphu 1003 426 (42.5) Ref. cat.
Lungthenphu 617 235 (38.1) 0.8 0.7 – 1.0
Age groups (yrs)
25-34 852 407 (47.8) 2.3 1.8 – 3.0
35-44 435 122 (28.0) Ref. cat.
≥45 333 132 (39.6) 1.7 1.2 – 2.3
Occupation
Housewife 1051 402 (38.2) Ref. cat.
Shopkeeper/saleswoman 161 77 (47.8) 1.6 1.1 – 2.3
Manual worker/Farmer 154 81 (52.6) 1.7 1.2 – 2.4
Clerical staff 110 44 (40.0) 1.0 0.6 – 1.5
Teacher/Health worker/Students 131 48 (36.7) 1.0 0.6 – 1.4
Ethnic group
Scharchop 605 226 (37.4) Ref. cat.
Ngalop 396 168 (42.4) 1.3 1.0 – 1.7
Lhotsampa 340 156 (45.9) 1.6 1.2 – 2.1
Other 274 106 (38.7) 1.1 0.8 – 1.5
Marital status
Married 1487 586 (39.4) Ref. cat.
Single 15 12 (80.0) 4.9 1.3 – 17.9
Widowed/separated 112 57 (50.9) 1.8 1.2 – 2.6
Pregnancies
0 93 63 (67.7) 1.9 1.2 -3.2
1 267 145 (54.3) Ref. cat.
2 442 182 (41.2) 0.7 0.5 – 0.9
≥3 809 263 (32.5) 0.6 0.4 – 0.8
χ21 for trend = 9.8, p = 0.002
b
Contraceptive method
None 343 194 (56.6) Ref. cat.
Hormonal 656 261 (39.8) 0.5 0.3 – 0.6
Other 606 196 (32.3) 0.4 0.3 – 0.5
Lifetime sexual partners
1 1420 568 (40.0) Ref. cat.
≥2 174 77 (44.2) 1.4 1.0 – 1.9
HPV infection
Negative 1254 479 (38.2) Ref. cat.
Positive 366 182 (49.7) 1.5 1.2 – 1.9
Note: Some figures do not add up to the total due to missing values; aAdjusted for age, as appropriate.
bTrend assessed among ever pregnant women only.
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Figure 2 Percentage of screened women by age group and years of education, 1,620 women (a); or years elapsed since last Pap
smear, 959 previously screened women (b); Thimphu and Lungthenphu, Bhutan.
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additional evidence [21,22] on the limitations, in terms
of population-based coverage, of mainly linking screen-
ing offer with attendance at perinatal care and family
planning clinics.
Manual workers, farmers, shop-keepers and saleswomen
reported previous screening less often than housewives
but this was not the case for clerical staff, teachers and
health workers. Economic reasons are unlikely to explain
lack of screening in Bhutanese women because of the uni-
versal access to free health care. However, inconvenientopening hours at screening clinics and earning losses from
attending may well discourage some women from being
screened. Interestingly, education level was associated with
screening attendance only among women aged 45 years or
above. A larger fraction of never-screened women was also
found in the Lhotsampa minority, a predominantly Hindu
ethnic group in a predominantly Buddhist country. Finally,
lack of previous screening was more frequent among
women at higher cervical cancer risk, i.e., the few who re-
ported two sexual partners or more and the many who
were HPV-positive.
Table 2 Odds ratio and 95% confidence interval for lack of prior screening by place invited and study participation,
1,503 women, Thimphu, Bhutan
Place of invitation Total Ever screened N. (%) Never screened N. (%) Odds ratioa 95% confidence interval
Clinic 778 457 (58.7) 321 (41.3) Ref. cat
Home, participants 225 120 (53.3) 105 (46.7) 1.3 1.0 - 1.7
Home, non-participants 500 126 (25.2) 374 (74.8) 4.3 3.4 - 5.6
Home, all 725 246 (33.9) 479 (66.1) 2.9 2.3 - 3.6
aAdjusted for age.
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and accepted by Bhutanese women. A recent report [10]
has explored knowledge on and attendance of cervical
cancer screening in university graduated, and mainly un-
married, women (mean age 23 years). The study revealed
that, despite national recommendations to start at age
20, approximately 95% of Bhutanese female university
graduates had never been screened. The most frequently
reported reasons for not attending screening were a) no
awareness of the need for a Pap smear (57%), b) embar-
rassment of being examined by male health professionals
(24%), and c) fear of being diagnosed with cancer (20%).
Similar reasons may explain lack of screening in a frac-
tion of women in our present study.
Like in most low/middle-income countries and in all
areas included in Figure 4, the population in the capital of
Bhutan is rapidly growing, census is incomplete, and ad-
dresses inaccurate. The national screening program does
not include an individual active call-and-recall system and
women are invited to join the screening program throughFigure 3 Percentage of screened women by place contacted, study pa variety of ways, e.g., mobilization at the community level,
leaflets, posters, and messages on media. An accurate esti-
mation of population-based screening coverage was,
therefore, lacking. We have clearly shown that past screen-
ing attendance among women who accepted to join our
study was affected by participation bias. Thanks to the in-
formation on screening history that was obtained during
home visits we have been at least partially able to over-
come this bias. Past screening attendance was 59% among
all participants but 34% in women contacted at home, and
only 25% in women contacted at home who refused to
participate in our study. Low screening attendance in
women age 45 or older is especially concerning as it points
to a large pool of undetected severe cancerous and pre-
cancerous cervical lesions in Thimphu [23]. Also of con-
cern, less than one third of women invited from home
joined our study.
Strengths of the present study include the large num-
ber and broad age range of participants, and the com-
bination of different sampling methods that gave us thearticipation, and age group, 1,503 women, Thimphu, Bhutan.
Figure 4 Percentage of women age ≥25 years who reported previous cervical cancer screening in low/middle-income countries.
IARC HPV surveys, 1997-2012.
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self-reported screening history could be made among
women who attended study clinics by crosschecking
women’s answers with the records of JDWNRH, De-
partment of Laboratory Services, the only cytology pro-
vider in Thimphu. Screening history collected at home
among non-participants may have been less accurate
than information obtained during study interview for
participants, as some women may not have fully under-
stood the question. Obviously, we have no information
on screening attendance among women who were
never found at home by social workers, despite re-
peated attempts.
Conclusions
The transition from an opportunistic screening to an all-
reaching population-based screening is yet to be
achieved in the capital of Bhutan, let alone in the entire
country. An active individual call and recall system has
been a key factor in improving screening coverage in
western countries [22] but invitation at home did not
work very well in never-screened women in Thimphu.
A wider offer of screening also outside maternal and
child health clinics, and better health education are
needed. Ad hoc methods to target never-screened women,
e.g., through campaigns set in working places, markets, re-
ligious events, and other public meeting places, are how-
ever the priority in Bhutan. As shown in the Netherlands[24], self-collection of vaginal samples in combination
with HPV testing may overcome women’s reluctance to
attend a gynaecological examination in Thimphu and also
facilitate the performance of cervical cancer screening in
rural and high-altitude areas in Bhutan.
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